东兴证券股份有限公司关于浙江东亚药业 股份有限公司使用银行承兑汇票支付募集资金 投资项目款项并以募集资金等额置换的核查意见 东兴证券股份有限公司(以下简称"东兴证券"或"保荐机构")作为浙江东 亚药业股份有限公司(以下简称"东亚药业"、"上市公司"或"公司"）向不特定对 象发行可转换公司债券的保荐机构,根据《证券发行上市保荐业务管理办法》、 《上海证券交易所股票上市规则》《上市公司监管指引第 2 号 -- 上市公司募 集资金管理和使用的监管要求》、《上海证券交易所上市公司自律监管指引第 11 号—持续督导》等有关法律法规的要求,就东亚药业使用银行承兑汇票支付募集 资金投资项目款项并以募集资金等额置换的事项进行了审慎核查,并发表意见如 下: 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意浙江东亚药业股份有限公司向不特 定对象发行可转换公司债券注册的批复》(证监许可(2023)1165 号),公司获 准向不特定对象发行可转换公司债券 690 万张,每张面值为人民币 100.00 元, 募集资金总额为人民币 69,000 万元,扣除发行费用人民币(不含增值税)981.56 万元后,实际募集资金净额为人民 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2023-055 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 第三届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江东亚药业股份有限公司（以下简称"公司"）第三届董事会第十八次会议 于 2023 年 8 月 10 日（星期四）在浙江省台州市黄岩区劳动北路 118 号总商会大厦 23 层会议室以现场结合通讯的方式召开。本次会议通知于 2023 年 7 月 31 日以电子 邮件的方式发出。本次会议应出席董事 7 人，实际出席董事 7 人。 会议由公司董事长池正明先生主持，监事、高管列席会议。本次会议的召集、 召开符合《中华人民共和国公司法》等法律、法规和《公司章程》的有关规定。 二、董事会会议审议情况 经各位董事认真审议，会议形成了如下决议： 具体内容详见公司披露于上海证券交易所网站的《关于使用银行承兑汇票支付募集 资金投资项 ...

浙江东亚药业股份有限公司 浙江东亚药业股份有限公司 关于 2023 年半年度募集资金存放与实际使用情况的专项报告 根据中国证券监督管理委员会（以下简称"中国证监会"）《上市公司监管 指引第 2 号——上市公司募集资金管理和使用的监管要求》和《上海证券交易所 上市公司自律监管指引第 1 号——规范运作》《上海证券交易所股票上市规则》 等有关规定，浙江东亚药业股份有限公司（以下简称"公司"、"本公司"）董 事会编制了《关于 2023 年半年度募集资金存放与实际使用情况的专项报告》。具 体如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 公司经中国证券监督管理委员会《关于核准浙江东亚药业股份有限公司首次 公开发行股票的批复》（证监许可[2020]2814 号）核准，由主承销商东兴证券股 份有限公司通过上海证券交易所系统采用网下向符合条件的投资者询价配售与 网上向持有上海市场非限售 A 股股份和非限售存托凭证市值的社会公众投资者 定价发行相结合方式，向社会公开发行了人民币普通股（A 股）股票 2,840.00 万 股，发行价为每股人民币为 31.13 元，共计募集资金总额为人民币 884,092,0 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2023-054 | | --- | --- | --- | | 债券代码：111015 | 转债简称：东亚转债 | | 浙江东亚药业股份有限公司 关于以集中竞价交易方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示：拟回购股份的用途：拟用于实施浙江东亚药业股份有限 公司（以下简称"公司"）员工持股计划或股权激励。 拟回购股份资金总额：不低于人民币 5,000 万元（含）且不超过人民币 10,000 万元（含）。 回购期限：自董事会审议通过本回购股份方案之日起不超过 12 个月。 回购价格：不超过人民币 39.18 元/股（含），该回购价格不超过董事会 通过回购股份决议前 30 个交易日公司股票交易均价的 150%。 回购资金来源：公司自有资金。 相关股东是否存在减持计划：经向公司董监高、控股股东、实际控制人、 持股 5%以上的股东发出问询函，问询在未来 3 个月、未来 6 个月是否存 在减持计划。截至第三届董事会第十七次会议 ...

浙江东亚药业股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江东亚药业股份有限公司（以下简称"公司"、"东亚药业"）近日收到 东兴证券股份有限公司（以下简称"东兴证券"）《关于更换浙江东亚药业股份 有限公司持续督导保荐代表人的函》。 东兴证券作为公司首次公开发行股票并上市的保荐机构，原指定阮瀛波先生、 张昱先生作为公司首次公开发行股票并上市项目保荐代表人，负责保荐工作及持 续督导工作，持续督导期至 2022 年 12 月 31 日。截至目前，公司首次公开发行 股票并上市的募集资金尚未使用完毕，根据相关规定，东兴证券对此未尽事项继 续履行持续督导义务。 | 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2023-052 | | --- | --- | --- | | 债券代码：111015 | 转债简称：东亚转债 | | 特此公告。 1 浙江东亚药业股份有限公司 董事会 2023 年 8 月 8 日 附件： 曾文倩女士简历 曾文倩女士，保荐代表人，经济学硕士，东兴 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2023-053 | | --- | --- | --- | | 债券代码：111015 | 转债简称：东亚转债 | | 浙江东亚药业股份有限公司 关于回购股份事项前十大股东和前十大无限售条件股东 持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2023 年 8 月 1 日，浙江东亚药业股份有限公司（以下简称"公司"）召开第三 届董事会第十七次会议，审议通过了《关于以集中竞价交易方式回购公司股份方 案的议案》，具体内容详见公司于 2023 年 8 月 2 日在上海证券交易所网站 （www.sse.com.cn）披露的《东亚药业关于以集中竞价交易方式回购公司股份方 案的公告》（公告编号：2023-051）。 浙江东亚药业股份有限公司 1 序号 股东名称 持股数量（股） 占公司总股本 的比例（%） 1 池正明 47,116,769 41.48 2 池骋 7,786,875 6.85 3 台州市瑞康投资合伙企业（有限合伙） 2,500,000 2.20 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥369,701,875.56, representing a 45.00% increase compared to the same period last year[5] - Net profit attributable to shareholders was ¥23,220,016.44, reflecting a 3.38% increase year-over-year[5] - The basic earnings per share remained at ¥0.20, unchanged from the previous year[6] - Total operating revenue for Q1 2023 reached RMB 369,701,875.56, a significant increase of 45% compared to RMB 254,966,058.04 in Q1 2022[19] - The net profit attributable to shareholders for Q1 2023 was CNY 23,220,016.44, compared to CNY 22,461,105.10 in Q1 2022, reflecting an increase of about 3.4%[21] - The company reported a total profit of CNY 26,360,261.89 for Q1 2023, slightly up from CNY 25,854,576.56 in Q1 2022, an increase of about 2.0%[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,510,323,347.67, an increase of 1.58% from the end of the previous year[6] - Total assets as of March 31, 2023, were RMB 2,510,323,347.67, compared to RMB 2,471,356,543.29 at the end of 2022, marking an increase of about 1.6%[17] - Total liabilities increased to RMB 647,314,075.24 from RMB 631,567,287.30, reflecting an increase of approximately 2.8%[17] - Non-current liabilities rose to RMB 84,864,150.76 from RMB 61,876,760.07, representing an increase of about 37%[17] Cash Flow and Working Capital - The net cash flow from operating activities was negative at -¥76,560,280.97, indicating a significant cash outflow[5] - The net cash flow from operating activities for Q1 2023 was negative CNY 76,560,280.97, worsening from negative CNY 14,747,411.47 in Q1 2022[24] - Cash and cash equivalents as of March 31, 2023, amounted to RMB 437,615,919.58, down from RMB 501,581,622.26 at the end of 2022, representing a decrease of approximately 12.7%[15] - Cash and cash equivalents at the end of Q1 2023 stood at CNY 437,615,919.58, down from CNY 497,876,603.38 at the end of Q1 2022, a decrease of about 12.1%[25] - Accounts receivable increased to RMB 185,439,119.64 from RMB 98,453,246.26, reflecting an increase of about 88.3% year-over-year[15] - Inventory decreased to RMB 458,031,512.77 from RMB 482,836,761.74, indicating a reduction of approximately 5.1%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,071[10] - The largest shareholder, Chi Zhengming, holds 41.48% of the shares, totaling 47,116,769 shares[11] - The company’s actual controllers are Chi Zhengming and Chi Cheng, holding a combined 48.33% of the shares[12] Operational Highlights - The increase in revenue was primarily driven by the new production line for cefazolin sodium intermediates, which significantly boosted production and sales compared to last year[9] - The company has not reported any significant new product developments or market expansions during this quarter[13] - The total operating costs for Q1 2023 were CNY 337,139,935.76, an increase from CNY 228,080,537.00 in Q1 2022, representing a growth of approximately 47.9%[20] - Research and development expenses rose to CNY 14,248,858.89 in Q1 2023, up from CNY 8,485,988.91 in Q1 2022, marking a significant increase of approximately 67.5%[20] Non-Recurring Items - Non-recurring gains and losses included a government subsidy of ¥1,462,109.01, contributing positively to the financial results[8] - The company incurred a credit impairment loss of CNY -5,577,518.48 in Q1 2023, compared to CNY -2,159,337.30 in Q1 2022, indicating a deterioration in credit quality[20]

Financial Performance - The company's operating revenue for 2022 was CNY 1,179,556,669.18, representing a year-on-year increase of 65.62%[23]. - The net profit attributable to shareholders for 2022 was CNY 104,423,862.82, an increase of 52.46% compared to the previous year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 96.55% to CNY 93,749,071.41 in 2022[23]. - The basic earnings per share for 2022 rose by 53.33% to CNY 0.92[24]. - The weighted average return on equity increased to 5.80%, up by 1.86 percentage points from the previous year[25]. - The total assets at the end of 2022 were CNY 2,471,356,543.29, a 9.79% increase from the end of 2021[23]. - The company's equity attributable to shareholders increased by 4.65% to CNY 1,839.79 million compared to the previous year[35]. - The company's total revenue for 2022 was 406,318.19 million CNY, with a gross margin of 35.23%[104]. Cash Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 2.9 per 10 shares, totaling RMB 32,944,000, subject to shareholder approval[5]. - The company will carry forward the remaining undistributed profits to future years[5]. - The company has no plans for stock dividends or capital reserve transfers in the current profit distribution proposal[5]. - The company's cash dividend distribution is based on achieving positive distributable profits and receiving an unqualified audit report[176]. - The company has a history of cash dividend distribution, with a cash dividend of 3.5 RMB per 10 shares distributed in 2021, totaling 39,760,000 RMB, which accounted for 34.73% of the net profit for 2020[184]. Audit and Compliance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[4]. - The financial report is guaranteed to be true, accurate, and complete by the board of directors and senior management[8]. - The company has established a strict internal control management system to enhance decision-making efficiency and ensure compliance and asset safety[191]. - The company received a standard unqualified opinion in the internal control audit report for 2022[192]. - The company has no significant deficiencies in internal control over subsidiaries during the reporting period[191]. Operational Risks and Challenges - There are no significant risks that materially affect the company's operations during the reporting period[8]. - The company faces risks from increasing competition in the raw materials and pharmaceutical intermediates market[135]. - The company is adapting to stricter regulatory requirements in the pharmaceutical industry, which may impact its operations[135]. - Environmental regulations are becoming stricter, increasing the pressure on the company to comply, which may lead to higher costs and impact profitability[140]. Research and Development - The company has over 30 invention patents and has been recognized as a national high-tech enterprise, indicating strong R&D capabilities[55]. - Research and development expenses increased by 20.53% to ¥44,947,984.62, indicating a continued investment in innovation[61]. - The company is focused on expanding its market presence through strategic partnerships and collaborations with downstream clients for product development[47]. - The company is investing in research and development to enhance its antibiotic portfolio, ensuring a strong market presence in the face of increasing competition[99]. Market Strategy and Expansion - The company plans to expand its production capacity for β-lactam antibiotics, which has been a significant driver of revenue growth[26]. - The company is focusing on expanding its market presence through strategic partnerships and potential acquisitions to enhance its competitive edge in the pharmaceutical industry[102]. - The company is committed to integrating high-end raw materials and formulations, aiming for a collaborative development of these products[131]. - The company is exploring potential mergers and acquisitions to strengthen its position in the pharmaceutical market[98]. Corporate Governance - The company has established a robust investor relations management system to maintain effective communication with investors and keep them informed about the company's operational developments[146]. - The company emphasizes respect for stakeholders, including customers, employees, suppliers, and the public, to promote sustainable development and enhance both economic and social benefits[146]. - The company has established a sound corporate governance structure, ensuring compliance with relevant laws and protecting shareholder rights[144]. - The company maintains independence from its controlling shareholder, ensuring no interference in decision-making and operations[145]. Environmental and Social Responsibility - The company invested 75.08 million yuan in environmental protection during the reporting period[194]. - The total non-methane hydrocarbon emissions for the year 2022 were 1.1012 tons, with an average emission concentration of 13.66 mg/m³[195]. - The total wastewater discharge for the year 2022 was 52,971.7436 tons, with a chemical oxygen demand average emission concentration of 209.95 mg/L[196]. - The company has no instances of exceeding pollutant discharge standards during the reporting period[196].

证券代码：605177 证券简称：东亚药业 公告编号：2023-026 浙江东亚药业股份有限公司 关于举办2022年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会 议 问 题 征 集 ： 投 资 者 可 于 2023 年 5 月 5 日 前 访 问 网 址 https://eseb.cn/12mYieqi3BK 或使用微信扫描下方小程序码进行会前提问，公司将 通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的问题进行回答。 一、说明会类型 浙江东亚药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 11 日在 上海证券交易所网站（www.sse.com.cn）披露了《2022 年年度报告》及《2022 年 年度报告摘要》。为便于广大投资者更加全面深入地了解公司经营业绩、发展战 略等情况，公司定于 2023 年 5 月 5 日（星期五）10:00-11:00 在"价值在线" （www.ir-online.cn）举办东亚药业（605177）2022 年度业绩说明会，与投资 ...

2022 年第三季度报告 证券代码：605177 证券简称：东亚药业 浙江东亚药业股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上 年同期增减变 | 年初至报告期 | 年初至报告 期末比上年 | | --- | --- | --- | --- | --- | | | | 动幅度(%) | 末 | 同期增减变 | | | | | | 动幅度(%) | | 营业收入 | 319,176,998.90 | 150.64 | 854,512,627.54 | 80.89 | ...